Molecular imaging of atherosclerosis with integrated PET imaging
Atherosclerotic diseases account for nearly half of all deaths and are leading causes of adult disability. Our understanding of how atherosclerosis leads to cardiovascular disease events has evolved: from a concept of progressive luminal narrowing, to that of sudden rupture and thrombosis of biologically active atheroma. In concert with this conceptual shift, contemporary imaging techniques now allow imaging of biological processes that associate with plaque instability: active calcification and plaque inflammation. This review focuses on opportunities provided by positron emission tomography/computed tomography, to identify these high-risk biological features of atherosclerosis.
KeywordsAtherosclerosis PET/CT imaging Echocardiography Myocardial perfusion imaging: SPECT Magnetic resonance imaging
Proprotein convertase subtilisin/kexin type 9
Positron emission tomography
Vascular cell adhesion molecules
Despite advances in cardiovascular therapeutics, atherosclerotic events, such as myocardial infarction (MI) and stroke, continue to account for nearly half of all deaths and are a leading cause of adult disability. Decades’ worth of scientific studies refined our understanding of how atherosclerotic disease results in atherothrombotic events: from a concept of progressive luminal narrowing to that of sudden rupture and thrombosis of biologically active atheroma. In concert with this conceptual shift, the approach to imaging atherosclerotic milieu has moved beyond lumenological imaging and now incorporates identification of high-risk features of the arterial wall, including structural features, along with key biological processes (such as active calcification and plaque inflammation).1,2 This review focuses on opportunities provided by positron emission tomography/computed tomography (PET/CT) to characterize such biological features of high-risk atherosclerotic plaque.
Atherosclerotic plaque biology3
Role of FDG-PET/CT in monitoring novel therapies1
Measurement of arterial inflammation with FDG-PET/CT has been shown to be highly reproducible. As a result, it has been widely employed as a research tool to assess the impact of anti-atherosclerotic interventions. A non-randomized single center FDG-PET/CT study first reported a reduction in arterial inflammation following 3 months of low-dose statin therapy. A subsequent multi-center study demonstrated a graded anti-inflammatory action of high-dose vs low-dose atorvastatin. These PET/CT findings are in concert with the wealth of clinical endpoint trial data showing statins’ beneficial impact on CVD events. Similarly thiazolidinediones have been shown to reduce arterial inflammation in patients with type 2 diabetes mellitus and significantly reduce CVD events in this group.
Conversely, a cholesterol ester transfer protein modulator (dalcetrapib), lipoprotein-associated phospholipase A2 inhibitor (rilapladib), and P-38 MAP kinase antagonists (BMS-582949 and losmapimod) each failed to significantly reduce arterial inflammation in PET/CT trials (with the notable exception of post hoc exploratory endpoints). Congruently, large clinical endpoint trials have shown that compounds in the same drug class so far also have failed to reduce CVD events. Accordingly, FDG-PET/CT trials have the potential to quantify therapeutic efficacy for novel drug discovery and treatment strategies.
Vascular calcification is another important feature of atherosclerotic disease. Importantly, the associated risk attributable to vascular calcification diverges according to the size of the calcification. Microcalcification (deposits of calcification smaller than 50 μm) occurs predominantly in the fibrous cap and may contribute to mechanical plaque destabilization while macrocalcification may confer plaque stability1. While macrocalcification is detectable using conventional medical imaging, microcalcification cannot be detected on structural imaging. New techniques are required in order to detect and quantify the microcalcification process non-invasively in vivo.
18F-sodium fluoride (NaF) is a PET/CT radiotracer used in oncology to detect metastatic bone spread, where 18F-fluoride replaces the hydroxyl groups in hydroxyapatite. Within atheroma, microcalcification is largely felt to be an active process driven by osteoblast-like cells derived from vascular smooth muscle, though passive deposition of calcium phosphate deposits resulting from phosphate release from necrotic cells may also play a role. It is believed that NaF is incorporated into hydroxyapatite at the sites of active microcalcification sites in a similar manner to that seen in its oncology applications. This process is likely accelerated by inflammation, with plaque macrophage burden strongly associated with osteoblastic activity in the aorta of hyperlipidemic mice.1
The development of techniques capable of imaging microcalcification has the potential to improve CVD risk, prognosis and guide the identification of new therapeutic strategies. Dweck et al. demonstrated that patients with higher vascular 18NaF uptake are more likely to have a clinical diagnosis of coronary artery disease and higher Framingham risk scores, with a correlation between NaF uptake and coronary artery calcium score, leading the authors to suggest NaF uptake could be used to refine CVD risk.
Several newer tracers have been evaluated for imaging high-risk biological features of atherosclerosis. 68Ga-DOTATATE targets the somatostatin receptor2, which is over-expressed in activated macrophages and endothelial cells responsible for inflammation and angiogenesis. This novel tracer has advantages over FDG for imaging coronary atheroma, since it is not taken up by myocardium. Additional tracers that target macrophages include 11C-PK11195 (targeting TSPO receptor), and 18F-FMCH (targeting macrophages cell membrane) have been shown in pre-clinical studies to localize to areas of active inflammation. Hypoxia within the plaque stimulates new vessel formation, increases LDL oxidation and promotes a pro-inflammatory response in macrophages. Hypoxia can be identified using 18F-fluoromisonidazole (18F-FMISO), a new tracer that identified cellular hypoxia as demonstrated by increased aortic uptake in an animal model fed an atherogenic diet. Neoangiogenesis can also be detected, using a tracer targeting integrin αvβ3expression (e.g., 68Ga-NOTA-RGD and 18F-Galacto-RGD).
As new therapies are developed (such as PCSK9 antagonists, along with other novel compounds drugs that may have more than minimal side effects), there will be a greater need for enhanced risk stratification. With such theoretical expansion of treatment options, there will be a need to better-match an individual’s risk against the cost and side effects of the new treatments. Additionally, imaging may be needed in order to assess whether the dose of the new therapies should be changed, or switched altogether, depending on changes seen on serial imaging, much the same way such decisions are made in oncologic diseases. Imaging biological features of atherosclerosis may contribute importantly to such enhanced risk assessment.
PET/CT imaging provides outstanding opportunities to assess atherosclerotic plaque biology non-invasively. Current use of FDG and NaF enables the early detection of atherosclerotic plaque inflammation and microcalcification. Such an approach enhances our assessment of individual risk, and may help identify new therapies. Additional studies are needed to delineate the potential clinical role of such approaches especially as armamentarium to treat atherosclerotic disease growth, placing demands on better delineation of risk and a better understanding of treatment response.
BH is supported by Research Training grant from Alexandria University. NRE is supported by a Research Training Fellowship from The Dunhill Medical Trust [Grant Number RTF44/0114]. JHFR is part supported by the NIHR Cambridge Biomedical Research Centre, the British Heart Foundation, EPSRC, and the Wellcome Trust. AT reports grants from NIH/NHLBI, Actelion, Genentech and Takeda, and personal fees from Actelion, Amgen AstraZeneca, and Takeda, all outside the submitted work.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.